Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/NB3 stock hub

FRA/NB3 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/NB3is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

13B

Frankfurt Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

FRA/NB3

In the news

Latest news · FRA/NB3

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E12.9

P25 n/aP50 n/aP75 n/a

Trailing P/E22.4

P25 n/aP50 n/aP75 n/a

ROE22.5

P25 n/aP50 n/aP75 n/a

ROIC23.7

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/NB3 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

213

Groups with data

Currency

USD

Showing 213 of 213 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	2,000
Employees Change	200%
Employees Change Percent	11.11
Enterprise value	EUR 12.3B
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 13B
Price	EUR 127
Price currency	EUR
Rev Per Employee	1,345,355.76x
Sic	2836
Symbol	fra/NB3
Website	https://www.neurocrine.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.46%
EV Earnings	21.18x
EV/EBIT	18.1x
EV/EBITDA	16.27x
EV/FCF	17.03x
EV/Sales	4.66x
FCF yield	5.54%
Forward P/E	12.91x
P/B ratio	4.4x
P/E ratio	22.43x
P/S ratio	4.83x
PE Ratio10 Y	154.83x
PE Ratio3 Y	38.65x
PE Ratio5 Y	94.5x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	25.75%
EBITDA Margin	26.71%
FCF margin	26.8%
Gross margin	64.37%
Gross Profit	EUR 1.7B
Gross Profit Growth	29.51%
Gross Profit Growth Q	68.05%
Gross Profit Growth3 Y	23.11%
Gross Profit Growth5 Y	21.81%
Net Income	EUR 579.9M
Net Income Growth	118.64%
Net Income Growth Q	2,405.06%
Net Income Growth3 Y	118.61%
Net Income Growth5 Y	10.71%
Pretax Margin	30.22%
Profit Margin	21.55%
Profit Per Employee	EUR 289,938
ROA	11.62
Roa5y	8.57
ROCE	19.6
ROE	22.5
Roe5y	12.08
ROIC	23.74
Roic5y	20.75

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	12.52%
Cagr15y	24.2%
Cagr1y	21.47%
Cagr20y	5.71%
Cagr3y	13.62%
Cagr5y	11.42%
EPS Growth	119.9
EPS Growth Q	2,310.5
EPS Growth3 Y	115.8
EPS Growth5 Y	9.71
FCF Growth	68.9%
FCF Growth Q	152.68%
FCF Growth3 Y	51.88%
FCF Growth5 Y	25.58%
OCF Growth	62.99%
OCF Growth Q	125%
OCF Growth3 Y	50.24%
OCF Growth5 Y	25.24%
Revenue Growth	28.59x
Revenue Growth Q	42.25x
Revenue Growth3 Y	24.74x
Revenue Growth5 Y	24.3x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.72
Assets	EUR 4.3B
Cash	EUR 1.1B
Current Assets	EUR 2.1B
Current Liabilities	EUR 705.2M
Debt	EUR 402M
Debt EBITDA	EUR 0.52
Debt Equity	EUR 0.14
Debt FCF	EUR 0.56
Equity	EUR 3B
Liabilities	EUR 1.3B
Long Term Assets	EUR 2.2B
Long Term Liabilities	EUR 594.7M
Net Cash	EUR 739.5M
Net Cash By Market Cap	EUR 5.69
Net Cash Growth	89.32%
Net Debt EBITDA	EUR -1.03
Net Debt Equity	EUR -0.25
Net Debt FCF	EUR -1.03
Tangible Book Value	EUR 3B
Tangible Book Value Per Share	EUR 29.38

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.93
Inventory Turnover	17.89
Net Working Capital	EUR 299.7M
Quick ratio	2.51
Working Capital	EUR 1.4B
Working Capital Turnover	EUR 1.98

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.68%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	225.31%
1Y total return	21.45%
200-day SMA	117
3Y total return	46.71%
50-day SMA	111.9
50-day SMA vs 200-day SMA	50under200
5Y total return	71.71%
All Time High	147.5
All Time High Change	-14.17%
All Time High Date	2025-02-03
All Time Low	1.32
All Time Low Change	9,487.12%
All Time Low Date	2009-11-13
ATR	2.38
Ch YTD	4.8
High	126.6
High52	137.7
High52 Date	2025-12-08
High52ch	-8.1%
Low	126.6
Low52	102.6
Low52 Date	2026-02-13
Low52ch	23.4%
Ma50ch	13.11%
Price vs 200-day SMA	8.18%
RSI	71.11
RSI Monthly	55.8
RSI Weekly	60.64
Sharpe ratio	0.63x
Sortino ratio	1.15
Total Return	0.68%
Tr YTD	4.8
Tr15y	2,480.02%
Tr1m	11.65%
Tr1w	13.19%
Tr3m	9.81%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 692.8M
Operating Income Growth	54.99
Operating Income Growth Q	684.8
Operating Income Growth3 Y	42.58
Operating Income Growth5 Y	21.63
Operating margin	25.75

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	99,291,905%
Shares Insiders	1.21%
Shares Institutions	100.25%
Shares Qo Q	-0.29%
Shares Yo Y	-0.68%
Short Ratio	4.68

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 528.2M
Average Volume	22.4x
Bv Per Share	29.38
CAPEX	EUR -28.1M
Ch10y	225.3
Ch15y	2,480
Ch1m	11.65
Ch1w	13.19
Ch1y	21.45
Ch20y	203.7
Ch3m	9.81
Ch3y	46.71
Ch5y	71.71
Ch6m	-5.03
Change	2.14%
Change From Open	0
Close	123.9
Days Gap	2.14
Depreciation Amortization	25,269,267.6
Earnings Date	2026-05-05
EBIT	EUR 692.8M
EBITDA	EUR 718.6M
EPS	EUR 5.64
F Score	6
FCF	EUR 721M
FCF EV Yield	5.87x
Financing CF	-5,637,450
Fiscal Year End	December
Founded	1,992
Graham Number	60.41763
Graham Upside	-52.26
Income Tax	EUR 233.2M
Investing CF	-680,657,040
Is Primary Listing	0
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Lynch Fair Value	EUR 60.43
Lynch Upside	-52.25
Ma150	117.3
Ma150ch	7.9%
Ma20	112.5
Ma20ch	12.53%
Net CF	62,792,520
Open	126.6
P FCF Ratio	18.04
P OCF Ratio	17.36
Ppne	456,203,556
Price Date	2026-05-08
Price EBITDA	EUR 18.1
Ptbv Ratio	4.4
Relative Volume	10.64x
Revenue	2,690,711,520x
SBC By Revenue	7.17x
Share Based Comp	192,800,790
Tax By Revenue	8.67x
Tax Rate	28.68%
Tr20y	203.7%
Tr6m	-5.03%
Z Score	6.99

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/NB3 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/NB3 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/NB3?

Insider, institutional, and short-interest positioning.

Institutional ownership

+100.2%

Share of float held by funds and institutions

Insider ownership

+1.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/NB3 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

71.1

Above 70: short-term overbought

Price vs 200-day MA

+8.2%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.63

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/NB3

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/NB3 stock rating?

fra/NB3 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/NB3 analysis?

The full report lives at /stocks/fra/NB3/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/NB3?

The latest report frames fra/NB3 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/NB3 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.